On 06/11/09, PPD, Inc. (Nasdaq:PPDI) announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China.

On 06/11/09, Imagenetix, Inc. (OTC:IAGX), announced William Spencer, President and CEO of Imagenetix, will be presenting the Company's store at the 2nd annual LD MICRO Conference on Thursday, December 3rd, at 10:30 AM PST at the Luxe Sunset in Los Angeles.

On 06/11/09, Amarin Corporation plc (NASDAQ:AMRN) announced the appointment of John F. Thero as the Company's Chief Financial Officer.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: M. Davila, Editor, BioMedReports.Com e-mail: support@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. In studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group.

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

             Contact   Imagenetix Investor Relations     William P. Spencer
                       (858)385-2797                Chief Executive Officer
                                                           Imagenetix, Inc.
                                                        Tel: (858) 674-8455

SOURCE Imagenetix, Inc.

http://www.imagenetix.net

Commenting on the results of the second quarter, Mr. William Spencer, Imagenetix Chief Executive Officer said, "We once again are encouraged by the increase in sales of our own branded product, InflameAway Celadrin, which continues to be well received in the food, drug and mass market segments. Also, we were pleased to introduce BioGuard, an immune boosting probiotic for the ear, nose and throat, into the largest club store warehouse during the quarter and the recent issuance of a patent for our early stage drug candidate, 1-TDC, to address periodontal diseases. We will continue to expand TV advertising to increase awareness of both InflameAway Celadrin and BioGuard. We anticipate this marketing program for the mass market segment to continue to result in improved sales. Our cash position was bolstered in early October as the result of entering into a supply buyout agreement with a customer."

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R). Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

    Contact   Imagenetix Investor Relations     William P. Spencer
              (858)385-2797                     Chief Executive Officer
                                                Imagenetix, Inc.
                                                Tel: (858) 674-8455

                            Imagenetix, Inc.
            Condensed Consolidated Statements of Operations
                (In thousands, except per share data)

                               Three Months Ended Six Months Ended
                                   September 30,   September 30,
                                   -------------   -------------
                                   2009    2008    2009    2008
                                   ----    ----    ----    ----

    Net sales                     $1,901  $2,656  $3,603  $4,051
      Cost of sales                1,040   1,541   2,095   2,361
                                   -----   -----   -----   -----
    Gross profit                     861   1,115   1,508   1,690
                                     ---   -----   -----   -----
    Gross profit percent            45.3%   42.0%   41.9%   41.7%

    Operating expenses:
      General and administrative     575     420   1,383   1,025
      Payroll expense                269     221     523     593
      Consulting expense             294     243     575     589
                                     ---     ---     ---     ---
    Operating expenses             1,138     884   2,481   2,207

    Operating income (loss)         (277)    231    (973)   (517)
      Other income                     1      10       2      17
      Settlement income            1,250       -   1,250   1,785
      Interest expense                 -       -      (2)     (1)
                                     ---     ---     ---     ---
    Income before income taxes       974     241     277   1,284
    Income tax expense               421      42     139     498
                                     ---     ---     ---     ---

    Net income                      $553    $199    $138    $786
                                    ----    ----    ----    ----

    Income per share:
      Basic                        $0.05   $0.02   $0.01   $0.07
      Diluted                      $0.05   $0.02   $0.01   $0.07

    Weighted average common
     shares outstanding:
      Basic                       11,011  10,984  11,011  10,972
      Diluted                     11,059  11,012  11,096  11,007



                               Imagenetix, Inc.
                     Condensed Consolidated Balance Sheets
                                (In thousands)

                                                    September 30, March 31,
                                                         2009      2009
                                                         ----      ----
    Assets:
      Current assets:
        Cash and cash equivalents                        $545     $1,226
        Accounts receivable, net                        1,088      1,096
        Other receivable                                1,250          -
        Inventories, net                                1,098      1,337
        Prepaid expenses and other current
         assets                                           225        109
        Deferred tax asset                                400        535
                                                          ---        ---
          Total current assets                          4,606      4,303

      Property and equipment, net                          99        116
      Long-term prepaid expenses                           24         30
      Other assets                                        121        134

                                                       ------     ------
          Total assets                                 $4,850     $4,583
                                                       ------     ------

    Liabilities and stockholders' equity:
      Current liabilities:
        Accounts payable                                 $497       $274
        Accrued liabilities                                83         81
        Income tax payable                                  -         70
        Customer deposits                                  37         59
        Contract payable                                    -         43
        Short term license payable                          -          3
                                                          ---        ---
          Total current liabilities                       617        530

      Stockholders' equity                              4,233      4,053

                                                       ------     ------
          Total liabilities and stockholders'
           equity                                      $4,850     $4,583
                                                       ------     ------

SOURCE Imagenetix, Inc.

http://www.imagenetix.net